scholarly journals Successful treatment of a massive pulmonary embolism using rivaroxaban in a patient with antithrombin III deficiency

2017 ◽  
Vol 16 (5) ◽  
pp. 144-147 ◽  
Author(s):  
Junji Yamaguchi ◽  
Nobuhiro Hara ◽  
Tetsuo Yamaguchi ◽  
Yasutoshi Nagata ◽  
Toshihiro Nozato ◽  
...  
1977 ◽  
Author(s):  
F. Josso ◽  
M. H. Aurousseau ◽  
A. M. Fischer ◽  
M. D. Dautzenberg ◽  
S. Beguin

High incidence of thromboembolism in observed in families with antithrombin III deficiency, despite the rather moderate defect (25 to 50 per cent) observed in the affected subjects, considered as heterozygous for the disease. The mechanism by which such a mild deficiency may promote thrombosis still remains unknown.A new family with antirhrombin III deficiency is reported, including three affected generations. Three young male adults of a same sibship died from massive pulmonary embolism aged from 22 to 28 years. In four living members of the family, three of which had antecedents of thrombophlebitis, antithrombin III level was close to 50 per cent by all assay methods used. Electro-phoretic and immunochemical studies failed to demonstrate any qualitative defect of the antithrombin III molecule.In these patients the only abnormalities of hemostasis lied in the early stage of the hemostatic pathway. In vitro, thrombin formation occured very rapidly after initiation of coagulation, as demonstrated by the kinetics of thrombin generation and factors V and VIII activation. In vivo, factors V and VIII were activated during bleeding much more rapidly than in controls and this activation was not suppressed by low doses of heparin (10 u./kg) as in the controls.These findings indicate that antithrombin III acts chiefly in the regulation balance of the early stages of hemostasis and thrombosis.


1977 ◽  
Author(s):  
Bruce Bennett ◽  
Michael Mackie ◽  
Alexander S. Douglas

A family living in Lewis (a Hebridean Island off the north west coast of Scotland) affected by antithrombin III deficiency has been studied. Two members have died, one of massive pulmonary embolism and one of major mesenteric infarction secondary to mesenteric vein occlusion. A further individual has sustained major small bowel infarction secondary to mesenteric vein thrombosis but survived after two small bowel resections followed by anticoagulant therapy. Other members of the family have suffered from nonfatal thrombotic events particularly during pregnancy. 57 individuals representing several generations have been studied and will be presented. Levels of antithrombin III measured by functional assays correlated well with those of antithrombin III measured immunologically. 12 members of the family showed moderate to severe deficiency of antithrombin III, the occurrence of thrombotic symptoms correlating well with deficiency of this protein. Transmission of the disorder as an autosomal dominant disorder is confirmed in the patients studied and by historical evidence over many generations.


2017 ◽  
Vol 119 (8) ◽  
pp. e55
Author(s):  
Ali Çoner ◽  
Davran Çiçek ◽  
Serhat Balcıoğlu ◽  
Sinan Akıncı ◽  
Haldun Müderrisoğlu

Author(s):  
O. Egeberg

Thrombophilia due to inherited deficiency of blood antithrombin III (AT III, heparin cofactor, anticonvertin) in a Norwegian family was published 1965, Thromb. D. h. 13, 516 & 14, 473. Only a few families with this defect have since then been described in different countries. In another Norwegian family, two sisters, age 42 and 30, and a brother, 35, have had episodes of venous thrombosis and pulmonary embolism from the age of 24–29. Their father suffered from thrombosis and died at 67. The two sisters have blood AT III level about half of normal average, measured with a two-stage coagulation assay. Data from both families are compatible with an autosomal dominant inheritance of the plasma protein deficiency. Venous thrombosis in the families is remarkably often complicated with embolizations; this might also relate to an inadequate platelet function. Platelet aggregation time of PRP with added thrombin or ADP was found prolonged. In coumarin treatment of the patients, AT III assaying gave increased levels.


1991 ◽  
Vol 4 (1) ◽  
pp. 63-68 ◽  
Author(s):  
MARTIN SIGMUND ◽  
MICHAEL RUBART ◽  
JUERGEN VOM DAHL ◽  
RAINER UEBIS ◽  
PETER HANRATH

Sign in / Sign up

Export Citation Format

Share Document